LONG MINI-FUTURE - GILEAD SCIENCES | Market Closed - Börse Stuttgart 15:41:46 2024-04-26 EDT | ||
| 1.11 EUR | +3.74% |
|
| Current month | -41.27% | ||
| 1 month | -36.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.11 | +3.74% | 0 |
| 24-04-25 | 1.07 | -13.01% | 0 |
| 24-04-24 | 1.23 | -2.38% | 0 |
| 24-04-23 | 1.26 | +0.80% | 0 |
| 24-04-22 | 1.25 | +2.46% | 0 |
Delayed Quote Börse Stuttgart
Last update April 26, 2024 at 03:41 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VA87VX |
| ISIN | DE000VA87VX6 |
| Date issued | 2018-11-01 |
| Strike | 53.79 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.78 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.7 € |
|---|---|
| Lowest since issue | 0.54 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
65.42
USD
Average target price
84.25
USD
Spread / Average Target
+28.78%
- Stock Market
- Certificates
- Certificat
